

### Resistance Associated Mutations in HCV Patients Failing ...

<https://pubmed.ncbi.nlm.nih.gov/33453702>

Currently, treatment of chronic hepatitis C is based on a combination of direct-acting antiviral agents (DAAs) which achieve HCV clearance in more than 95% of patients. Despite this high rate of cure, treatment failures can occur in about 3-5% of treated patients. Resistance associated substitutions (RAS) are commonly detected after virological failure, although their role in real-life DAA failures is ...

### Hepatitis C virus drug resistance associated substitutions ...

<https://pubmed.ncbi.nlm.nih.gov/29525636>

The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virological cure.

Cited by: 126

Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...

Publish Year: 2018

### Hepatitis C Virus Resistance Testing in Genotype 1: The ...

<https://pubmed.ncbi.nlm.nih.gov/28480743>

Conclusions: Baseline resistance testing was used for decisional support for 3 clinical scenarios in patients with HCV genotype 1 infection at the time of manuscript submission. Pending the approval of 2 new direct-acting antiviral regimens in the third quarter of 2017, the rapidly evolving HCV treatment guidelines will likely reflect a decreased clinical utility for resistance testing.

Cited by: 7

Author: Suzanne Molino, Suzanne Molino, Michel...

Publish Year: 2017

### How much of a problem is resistance in treating hepatitis C?

<https://www.ncbi.nlm.nih.gov/pubmed/27673712>

These resistance-associated substitutions (RASs) may exist prior to treatment, and are associated with, but do not inevitably result in, treatment failure. The most important RASs with current regimens occur in the NS5A protein of viral variants, which may persist for years after treatment.

Cited by: 4

Author: Daniel M. Forton

Publish Year: 2016

### Hepatitis C virus drug resistance associated substitutions ...

国内版

国际版

Microsoft Bing

Hepatitis C Virus Failure to Treatment: Clinical Utility of Testing Res

🔍

🔍

🔍

Sign in

☰

ALLIMAGESVIDEOS

34,000 ResultsAny time ▾

Hepatitis C Virus Resistance Testing in Genotype 1: The ...

<https://pubmed.ncbi.nlm.nih.gov/28480743>

Objective: To review the role and utility of baseline **resistance testing** with currently available and pipeline genotype 1 **hepatitis C virus (HCV) treatment**. Data sources: Authors reviewed liver meeting abstracts for data on currently-available and pipeline genotype 1 retreatment regimens from January 1, 2015, to March 23, 2017. Additional trials were identified from a review of ...

Cited by: 7Author: Suzanne Molino, Suzanne Molino, Michel ...

Publish Year: 2017

Resistance Mechanisms in Hepatitis C Virus: implications ...

<https://pubmed.ncbi.nlm.nih.gov/28497432>

Multiple direct-acting antiviral (DAA)-based regimens are currently approved that provide one or more interferon-free **treatment options** for **hepatitis C virus (HCV)** genotypes (G) 1-6. The choice of a DAA regimen, duration of therapy, and use of **ritonavir** depends on multiple viral and host factors, including HCV genotype, the detection of **resistance-associated** amino acid (aa) substitutions (RASs), prior treatment ...

Cited by: 27Author: Sabrina Bagaglio, Caterina Uberti-Foppa, ...

Publish Year: 2017

PEOPLE ALSO ASK

Is there a way to test for resistance to HCV?


▼

How is resistance used to test hepatitis C?

▼

Hepatitis C virus

Rna Virus



Wikipedia

Higher classification: [Hepacivirus](#)

Scientific name: Hepatitis C Virus

Family: [Flaviviridae](#)

Domain: [Virus](#)

Phylum: [Kinetoviricota](#)

Kingdom: [Orthomavirae](#)

Data from: [Wikipedia](#) [Freebase](#)

[Suggest an edit](#)

The hepatitis C virus is a small, enveloped, positive-sense single-stranded RNA virus of the family [Flaviviridae](#). The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer and lymphomas in humans.



国内版

国际版

Hepatitis C virus failure to treatment: Clinical utility of testing resist



ALL

IMAGES

VIDEOS

11,400 Results

Any time ▾

### Hepatitis C virus drug resistance associated substitutions ...

<https://www.sciencedirect.com/science/article/pii/S1368764618300128>

Mar 01, 2018 · The ability of some RASs to confer resistance to multiple DAAs, as well as the potential development of complex multiclass-resistance patterns at failure, makes HCV resistance testing an important diagnostic tool to tailor second line therapy and improve chances of virological success, especially when simultaneously performed on NS3, NS5A and NS5B (Vigano et al., 2017). The present manuscript aims to assist virologist and clinicians in the interpretation of HCV resistance testing ...

Cited by: 142

Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...

Publish Year: 2018

### Hepatitis C virus drug resistance associated substitutions ...

<https://pubmed.ncbi.nlm.nih.gov/29525636>

The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virological cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or ...

Cited by: 142

Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...

Publish Year: 2018

### Hepatitis C Virus Resistance Testing in Genotype 1: The ...

<https://pubmed.ncbi.nlm.nih.gov/28480743>

Objective: To review the role and utility of baseline resistance testing with currently available and pipeline genotype 1 hepatitis C virus (HCV) treatment. Data sources: Authors reviewed liver meeting abstracts for data on currently-available and pipeline genotype 1 retreatment regimens from January 1, 2015, to March 23, 2017. . Additional trials were identified from a review of ...

Cited by: 7

Author: Suzanne Molino, Suzanne Molino, Michel...

Publish Year: 2017

### Complex Pattern of Resistance-Associated Substitutions of ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165339>

Oct 24, 2016 · Backgrounds & Aims We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS5B inhibitor, sofosbuvir (SOF) in patients with HCV genotype 1. ...